Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2009
11/18/2009CN101579349A Traditional Chinese medicine preparation
11/18/2009CN101579348A Application of 3,6'-disinapoyl sucrose (DISS) in preparing product for treating tristimania
11/18/2009CN101579344A Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
11/18/2009CN101579343A Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
11/18/2009CN101579319A Medical prescription of catalpol freezing-drying powder for injection and preparation method
11/18/2009CN101579318A Bulleyaconitine A lipidosome freeze-dried powder injection and preparation method thereof
11/18/2009CN100560718C Use of protocatechuic acid in accelerating nerve stem cell multiplication in vitro and inducement differentiation
11/18/2009CN100560585C New benzimidazole derivative
11/18/2009CN100560566C Benzyloxy derivatives as MAOB inhibitors
11/18/2009CN100560103C Ointment of diminishing gore and preparing method
11/18/2009CN100560080C Composition containing nucleoside and its preparing method
11/18/2009CN100560074C External patch containing estrogen and/or progestogen
11/18/2009CN100560068C Levogyration sulpiride injection preparation method
11/18/2009CN100560065C Asarone fatty emulsion and its preparing method
11/18/2009CN100560064C Method for preparing flupentixol and melitracen capsule
11/18/2009CN100559997C Hypertensive tranquilizing pillow
11/17/2009US7619097 N-(trans-2,3-di-n-amyl-2-butenoic acid amide)-L-phenylglycinamide;treating hypertension, deficiency of magnesium ion bound to the plasma membranes of their somatic cells; sodium-sensitive essential hypertension and Type 2 insulin-resistant diabetes mellitus
11/17/2009US7619096 3-Aminopyrrolidines as inhibitors of monoamine uptake
11/17/2009US7619091 Treating nervous system disorders such as mild cognitive impairment, Alzheimer's disease or dementia associated with Down syndrome; e.g. use of 5,7-dichloro-8-hydroxy-2-(2-pyridyl)-quinoline (PBT 1052)
11/17/2009US7619089 Formulations and use of e.g. 2-chloro-N-(8 alpha ,9S)cinchonan-9-yl)-3-trifluoromethyl-benzamide hydrochloride for treating pain, Parkinson's disease, epilepsy, sleep apnea, alcoholism, psychological disorders, migraines
11/17/2009US7619065 Cystine-knot fold protein
11/17/2009US7619006 Conjugates with organic acids; uses thereof in the treatment of psychotic and/or proliferative disorders and diseases and as chemosensitizing agents; the organic acids are selected to reduce side effects induced by the psychotropic drugs and/or to exert an anti-proliferative activity
11/17/2009US7618988 Use of substituted aminomethyl chromans
11/17/2009US7618967 Indane compounds
11/17/2009US7618961 A sulfonylamino-tetrahydro(1,3)thiazolo(5,4-c)pyridinyl or benzothiazole derivatives, for treating diabetes, syndrome X, obesity, glaucoma, hyperlipidemia, hyperglycemia, hyperinsulinemia, osteoporosis, tuberculosis, dementia
11/17/2009US7618958 Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects
11/17/2009US7618791 Detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells
11/17/2009US7618787 Method of screening compound capable of accelerating or inhibiting apoptosis, apoptosis accelarator and apoptosis inhibitor
11/17/2009US7618634 Neurotoxic oligomers
11/17/2009US7618629 Manipulation of cytokine levels using CD83 gene products
11/17/2009US7618621 Preparing culture of pluripotent brain tissue for nervous tissue regeneration, tissue engineering and treating nervous system disorders
11/17/2009CA2522051C Diamine derivative, production process therefor and antioxidant
11/17/2009CA2470519C Heteroaryl substituted pyrrole modulators of metabotropic glutamate receptor-5
11/17/2009CA2450801C Drugs that enhance synaptic responses mediated by ampa receptors
11/17/2009CA2441239C Mch antagonists and their use in the treatment of obesity
11/17/2009CA2432181C Substituted pyrroloquinolines and pyridoquinolines as serotonin agonists and antagonists
11/17/2009CA2417082C New benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors
11/17/2009CA2411368C Therapeutic combinations of fatty acids
11/17/2009CA2407094C Diazabicyclic central nervous system active agents
11/17/2009CA2400117C Novel collagen-like protein clac, a precursor thereof, and genes encoding the same
11/17/2009CA2393809C Heterocyclic dihydropyrimidines as potassium channel inhibitors
11/17/2009CA2379365C Transnasal anticonvulsive compositions and modulated process
11/17/2009CA2374158C Indole derivatives
11/17/2009CA2369997C Compositions and methods for treating amyloidosis
11/17/2009CA2352494C Compositions and methods for the treatment of alzheimer's disease, central nervous system injury, and inflammatory diseases
11/17/2009CA2336822C Method of treatment and pharmaceutical composition
11/17/2009CA2321198C 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives as muscarinic receptor antagonists
11/17/2009CA2272460C Pyridin-2-yl-methylamine derivatives, method of preparing and application as medicine
11/17/2009CA2259583C Azolo triazines and pyrimidines
11/17/2009CA2206794C Novel 3,5-dioxo-(2h,4h)-1,2,4-triazine derivatives, their preparation and use as drugs
11/12/2009WO2009137843A2 Nmda receptor antagonists for the treatment of neuropsychiatric disorders
11/12/2009WO2009137795A2 Methods for treating endoplasmic reticulum (er) stress disorders
11/12/2009WO2009137782A2 Allosteric enhancers of the a1 adenosine receptor
11/12/2009WO2009137404A1 Urea compounds as gamma secretase modulators
11/12/2009WO2009137251A2 Cysteine and cystine bioisosteres to treat schizophrenia and reduce drug cravings
11/12/2009WO2009137086A1 Oral administration of peripherally-acting opioid antagonists
11/12/2009WO2009136850A1 Muscarinic receptor agonits useful in the treatment of pain, alzheimer's disease and schizophrenia
11/12/2009WO2009136814A1 Tetrahydro-pyrazolo[1,5-a]pyrido-pyrimidines as antagonists of serotonin 5-ht6 receptors, methods for the production and use thereof
11/12/2009WO2009136813A1 2-amino-3-sulphonyl-tetrahydro-pyrazolo[1,5-a]pyrido-pyrimidine antagonists of serotonin 5-ht6 receptors, methods for the production and use thereof
11/12/2009WO2009136625A1 Cyclic amine-1-carboxylic acid ester derivative and pharmaceutical composition containing the same
11/12/2009WO2009136611A1 Glutathione production enhancer, prophylactic/therapeutic agent for diseases associated with lack of glutathione, and food, beverage and feed
11/12/2009WO2009136396A2 Sulfobetaines for therapy
11/12/2009WO2009136350A1 Novel class of spiro piperidines for the treatment of neurodegenerative diseases
11/12/2009WO2009135944A1 Trisubstituted pyrazoles as acetylcholine receptor modulators
11/12/2009WO2009135927A1 Substituted n-phenyl-2,3-dihydroimidazo[2,1-b]thiazole-5-sulfonamide derivatives as 5-ht6 ligands
11/12/2009WO2009135925A1 Substituted n-imidazo[2,1-b]thiazole-5-sulfonamide derivatives as 5-ht6 ligands
11/12/2009WO2009135842A1 Azetidines and cyclobutanes as histamine h3 receptor antagonists
11/12/2009WO2009135495A1 Method for treating cognitive deficits
11/12/2009WO2009135322A1 Methods and compositions for the treatment of huntington's disease
11/12/2009WO2009135258A1 Methods and compositions for the management of pain using omega-conotoxins
11/12/2009WO2009116074A3 Substituted benzimidazoles as cannabinoid modulator
11/12/2009WO2009108632A9 Compositions and methods for using stromal cells to enhance treatment of central nervous system injuries
11/12/2009WO2009099672A3 Breaking immunological tolerance with a genetically encoded unnatural amino acid
11/12/2009WO2009085200A3 Anti-amyloid antibodies and uses thereof
11/12/2009WO2009071691A3 Oxindole derivatives and the use thereof as a medication
11/12/2009WO2009070311A3 Crystal forms of o-desmethylvenlafaxine fumarate
11/12/2009WO2009046377A3 Compositions and methods of stem cell therapy for autism
11/12/2009WO2009043519A3 Use of band 3 protein and pacap-27 as a therapeutic agent
11/12/2009WO2009043454A3 Use of pacap-27 as a therapeutic agent
11/12/2009WO2009039976A3 Use of a peptide as a therapeutic agent
11/12/2009WO2009033757A3 Use of mage-3 antigen (271-279) as a therapeutic agent
11/12/2009WO2009033756A3 Use of oxyntomodulin alone or in combination with melanotropin potentiating factor as a therapeutic agent
11/12/2009WO2009033750A3 Use of phm-27 alone or in combination with leu-enkephalin as a therapeutic agent
11/12/2009WO2009033711A3 Use of glp-1 as a therapeutic agent
11/12/2009WO2008133344A3 Piperidine derivative and use thereof
11/12/2009WO2008121860A9 Peripheral opioid receptor antagonists and uses thereof
11/12/2009US20090282495 Neurotrophic factor manf and uses thereof
11/12/2009US20090281310 Cinnamide compound
11/12/2009US20090281194 Combinations for treating HIV-associated pain
11/12/2009US20090281193 Process for the Preparation of and Crystalline Forms of Optical Enantiomers of Modafinil
11/12/2009US20090281192 Process for the Preparation of and Crystalline Forms of Optical Enantiomers of Modafinil
11/12/2009US20090281179 Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache associated pain
11/12/2009US20090281178 Compounds for Lysosomal Modulation and Methods of Use
11/12/2009US20090281170 Polynucleotide therapy
11/12/2009US20090281165 Antisense oligonucleotide against human acetylcholinesterase (AChE) and uses thereof
11/12/2009US20090281164 RNA INTERFERENCE MEDIATED INHIBITION OF RESPIRATORY SYNCYTIAL VIRUS (RSV) EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
11/12/2009US20090281152 Indole Compounds Having Affinity to the EP1 Receptor
11/12/2009US20090281147 Method of treating of demyelinating diseases or conditions
11/12/2009US20090281145 Allosteric enhancers of the a1 adenosine receptor
11/12/2009US20090281137 Indol-2-one derivatives for the treatment of central nervous disorders, gastrointestinal disorders and cardiovascular disorders
1 ... 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 ... 1833